83例单倍体相合造血干细胞移植治疗恶性血液病的临床疗效及预后分析

发布时间：2018-05-14 13:06

  本文选题：单倍体相合异基因造血干细胞移植 + 移植物抗宿主病　； 参考：《中国实验血液学杂志》2016年03期

【摘要】：目的:进一步总结单倍体相合造血干细胞移植的临床经验,并探讨其疗效。方法:比较83例单倍体移植和本移植中心同期73例同胞全相合移植的疗效,并分析影响移植后生存的相关危险因素。结果:单倍体移植组与全相合移植组在造血重建、发生移植物抗宿主病(GVHD)、总生存(OS)、无病生存(DFS)、移植后复发及移植相关死亡率(TRM)等方面均无显著性差别;多因素分析显示,移植前的疾病状态、移植后复发及出现Ⅲ-Ⅳ度急性GVHD是影响移植后生存的危险因素,相对风险(RR)分别为3.1(95%CI,1.7-5.4),3.5(95%CI,2.0-6.2)和2.5(1.4-4.6)(P0.05)。结论:应用现有的移植体系进行单倍体移植的疗效与同胞全相合移植相当,移植前的疾病状态及移植后是否出现重度急性GVHD对移植后患者的生存具有重要意义。
[Abstract]:Objective: to summarize the clinical experience of haploid compatible hematopoietic stem cell transplantation (HSCT) and to explore its curative effect. Methods: 83 cases of haploid transplantation and 73 cases of sibling complete transplantation in the same period were compared, and the risk factors affecting survival after transplantation were analyzed. Results: there were no significant differences in hematopoietic reconstitution, GV HDV, total survival, disease-free survival (DFSN), post-transplant recurrence and transplantation-related mortality (TRM) between the haploid transplantation group and the homozygous transplantation group. The state of disease before transplantation, recurrence after transplantation and occurrence of grade 鈪，

本文编号：1887969